ES2566337T3 - Sales del ácido (S)-2-amino-3-{4-[4-(2,4-dioxo-tiazolidin-5-ilmetil)-fenoxi]-fenil} propiónico y su éster de metilo como inhibidores de interleucinas para el tratamiento de la obesidad o de la diabetes - Google Patents

Sales del ácido (S)-2-amino-3-{4-[4-(2,4-dioxo-tiazolidin-5-ilmetil)-fenoxi]-fenil} propiónico y su éster de metilo como inhibidores de interleucinas para el tratamiento de la obesidad o de la diabetes Download PDF

Info

Publication number
ES2566337T3
ES2566337T3 ES06735487.8T ES06735487T ES2566337T3 ES 2566337 T3 ES2566337 T3 ES 2566337T3 ES 06735487 T ES06735487 T ES 06735487T ES 2566337 T3 ES2566337 T3 ES 2566337T3
Authority
ES
Spain
Prior art keywords
mhz
yield
phenyl
phenoxy
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06735487.8T
Other languages
English (en)
Spanish (es)
Inventor
Bishwajit Nag
Abhijeet Nag
Debendranath Dey
Shiv Kumar Agarwal
Partha Neogi
Gaddam Om Reddy
Sangamesh Badiger
Gajendra Singh
Surendra Kumar Pandey
Santhanagopalan Chithra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bexel Pharmaceuticals Inc
Original Assignee
Bexel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bexel Pharmaceuticals Inc filed Critical Bexel Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2566337T3 publication Critical patent/ES2566337T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ES06735487.8T 2005-02-17 2006-02-17 Sales del ácido (S)-2-amino-3-{4-[4-(2,4-dioxo-tiazolidin-5-ilmetil)-fenoxi]-fenil} propiónico y su éster de metilo como inhibidores de interleucinas para el tratamiento de la obesidad o de la diabetes Expired - Lifetime ES2566337T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
INDE03472005 2005-02-17
IN347DE2005 2005-02-17
US11/096,718 US7521465B2 (en) 2003-01-17 2005-03-31 Diphenyl ether derivatives
US96718 2005-03-31
PCT/US2006/005846 WO2006089225A1 (en) 2005-02-17 2006-02-17 5- [4- (4- (2 -amino- 2 -methoxycarbonylethyl) phenoxy) benzilidene] thiazolidin-2 , 4-dion e derivatives and related compounds for reducing glucose, cholesterol and triglyceride levels in plasma

Publications (1)

Publication Number Publication Date
ES2566337T3 true ES2566337T3 (es) 2016-04-12

Family

ID=36570583

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06735487.8T Expired - Lifetime ES2566337T3 (es) 2005-02-17 2006-02-17 Sales del ácido (S)-2-amino-3-{4-[4-(2,4-dioxo-tiazolidin-5-ilmetil)-fenoxi]-fenil} propiónico y su éster de metilo como inhibidores de interleucinas para el tratamiento de la obesidad o de la diabetes

Country Status (9)

Country Link
US (1) US7521465B2 (https=)
EP (1) EP1848700B1 (https=)
JP (1) JP5134974B2 (https=)
KR (1) KR20070105364A (https=)
CA (1) CA2598087C (https=)
ES (1) ES2566337T3 (https=)
HU (1) HUE028882T2 (https=)
PL (1) PL1848700T3 (https=)
WO (1) WO2006089225A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US9969977B2 (en) * 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US7781464B2 (en) 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7521465B2 (en) 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
WO2008019306A2 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
US20090069313A1 (en) * 2007-09-06 2009-03-12 Orchid Research Laboratories Ltd. Novel MAO-A inhibitors
ATE536347T1 (de) 2008-05-20 2011-12-15 Merck Sharp & Dohme Effiziente herstellung heterologer proteine unter verwendung von mannosyltransferaseinhibitoren
US20140187594A1 (en) * 2010-07-28 2014-07-03 Orchid Chemicals And Pharmaceuticals Ltd Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
JP6014816B2 (ja) 2011-05-10 2016-10-26 国立大学法人神戸大学 Ｒａｓ機能阻害作用を有するチオキソチアゾリジン誘導体
EP4029859A1 (en) 2014-11-21 2022-07-20 Bsim Therapeutics, S.A. 2-oxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
TW202019923A (zh) * 2018-07-16 2020-06-01 義大利商吉斯藥品公司 作為Ｒｈｏ－激酶抑制劑之酪胺酸醯胺衍生物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0228168A (ja) * 1988-04-14 1990-01-30 Sankyo Co Ltd チアゾール誘導体
US20020049240A1 (en) 1994-12-19 2002-04-25 Beecham Group P.1.C. Novel compounds
US5166137A (en) 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
TW268952B (https=) 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
US5527546A (en) 1994-08-10 1996-06-18 Bayer Corporation Human interleukin 6 inhibitor
JP4173539B2 (ja) 1995-05-11 2008-10-29 ラボラトアール・セローノ・ソシエテ・アノニム Ｉｌ−６活性阻害剤
TW577875B (en) 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
US6699896B1 (en) 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
TR200003595T2 (tr) 1998-06-05 2001-07-23 Astrazeneca Ab Kimyasal bileşikler
WO2000000194A1 (en) 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
US6664281B1 (en) 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
ES2343104T3 (es) 1999-04-07 2010-07-23 Daiichi Sankyo Company, Limited Derivados de amina.
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
TWI284533B (en) 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
EP1109796A1 (en) 1999-07-01 2001-06-27 Geron Corporation Telomerase inhibitors and methods of their use
HUP0202520A3 (en) 1999-08-23 2004-11-29 Kyorin Seiyaku Kk Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them
NZ517993A (en) 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
JP2001199888A (ja) 2000-01-24 2001-07-24 Fujimoto Brothers:Kk 糖尿病治療剤
JP2001308814A (ja) 2000-04-19 2001-11-02 Hitachi Ltd フレーム構成自動識別通信装置
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
ATE310733T1 (de) 2000-04-21 2005-12-15 Pfizer Prod Inc Thyroid-rezeptorliganden
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DE60220424T2 (de) 2001-09-14 2008-03-06 Novo Nordisk A/S NEUE LIGANDEN FÜR DIE HisB10 Zn2+ STELLEN DES INSULIN-HEXAMERS IN DER R-KONFORMATION
AU2002352706A1 (en) * 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
US7521465B2 (en) 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US6794401B2 (en) 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
EP1610812A1 (en) 2003-03-11 2006-01-04 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin
US7087576B2 (en) 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers

Also Published As

Publication number Publication date
CA2598087A1 (en) 2006-08-24
EP1848700B1 (en) 2015-12-30
JP2008530242A (ja) 2008-08-07
HUE028882T2 (en) 2017-01-30
CA2598087C (en) 2014-05-27
US20050288341A1 (en) 2005-12-29
KR20070105364A (ko) 2007-10-30
WO2006089225A1 (en) 2006-08-24
JP5134974B2 (ja) 2013-01-30
US7521465B2 (en) 2009-04-21
PL1848700T3 (pl) 2016-08-31
EP1848700A1 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
ES2566337T3 (es) Sales del ácido (S)-2-amino-3-{4-[4-(2,4-dioxo-tiazolidin-5-ilmetil)-fenoxi]-fenil} propiónico y su éster de metilo como inhibidores de interleucinas para el tratamiento de la obesidad o de la diabetes
US8501960B2 (en) Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
RU2494090C2 (ru) Способ получения производных r-бета-аминофенилмасляной кислоты
CN102838523A (zh) 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途
ES2659337T3 (es) Derivados de quinazolina y su uso como inhibidores de ADN metiltransferasa
ES2633838T3 (es) Método para preparar derivados tricíclicos
ES2597652T3 (es) Síntesis optimizada de ácidos biliares puros, cristalinos, no polimórficos, con tamaño de partícula definido
Looper et al. Syntheses of the cylindrospermopsin alkaloids
CN103387601B (zh) 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
ES2991081T3 (es) Procedimiento para preparar 2-(3,5-diclorofenil)-6-benzoxazolcarboxilato de 1-desoxi-1-metilamino-D-glucitol
US9771317B2 (en) Process for preparing lacosamide and related compounds
JP4393376B2 (ja) フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用
US10676443B2 (en) Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile
EA024688B1 (ru) Способ получения ситаглиптина и его фармацевтически приемлемых солей
CN113234037A (zh) Z-2-(2-酰基亚甲基)噻唑烷-4-酮类衍生物及其制备方法和应用
TWI290554B (en) Process for preparation 5-(1-piperazinyl)-benzofuran-2-carboxamide by transition metal-catalyzed amination
CN100480234C (zh) N-(n-苯甲酰基-苯丙氨酰基)-苯丙氨酸二肽衍生物及其制备方法和用途
US20240300930A1 (en) Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
WO2011065420A1 (ja) ６－置換－１－メチル－１ｈ－ベンズイミダゾール誘導体の製造法及びその製造中間体
ES2912409T3 (es) Intermedios y procesos para la preparación de linagliptina y sus sales
JP2006500409A5 (https=)
CN101445468A (zh) 对氨基苯甲酸拟二肽酯及其制备方法和应用
EP1511728B1 (fr) Derives d oxophenyl-cyclohexyl-propanolamine, leur preparati on et leur application en therapeutique
CN103421083A (zh) 具有1,2,3-三氮唑结构的抗登革热病毒杂环肽类化合物及其制备方法和用途
EP2956438A2 (fr) Procédé de synthèse de 4-piperidin-4-yl-benzène-1,3-diol et de ses sels et nouveau composé 4-(2,4-dihydroxy-phényl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle